-

Bruker Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:

2024 Jefferies Global Healthcare Conference, New York, NY
Thursday, June 6, 2024, at 7:30 a.m. Eastern Time
Frank Laukien, Chairman, President and Chief Executive Officer
Juergen Srega, President, Bruker CALID Group

45th Annual Goldman Sachs Global Healthcare Conference, Miami, FL
Wednesday, June 12, 2024, at 11:20 a.m. Eastern Time
Gerald Herman, Executive Vice President and Chief Financial Officer

Live audio webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for at least 30 days following the presentations.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. Br...

Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

INNSBRUCK, Austria--(BUSINESS WIRE)--Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classe...

Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics

BALTIMORE--(BUSINESS WIRE)--At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced significant further advances in ultra-high sensitivity 4D-Proteomics™ with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF® methods for key biological and clinical research problems with very low sample amounts. N...
Back to Newsroom